Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diabetes drug
Biotech
Novo Nordisk axes once-monthly GLP-1/GIP agonist MASH prospect
Novo Nordisk has ended development of a drug candidate that it singled out as an exciting part of its pipeline earlier this year.
Nick Paul Taylor
Aug 7, 2024 7:00am
Diabetes biotech stock tanks as FDA imposes full clinical hold
Jun 7, 2024 8:13am
A 'live fire exercise' with COVID preps SAB for new (old) focus
Oct 16, 2023 6:00am
Lilly brushes off liver tox worries as Pfizer drops obesity drug
Aug 8, 2023 10:51am
Lilly's next obesity drug just cut an average of 58 pounds
Jun 26, 2023 8:45pm
Lilly drops program against NASH target that caught Pfizer's eye
Feb 2, 2023 8:45am